The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers
Official Title: Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid
Study ID: NCT04750109
Brief Summary: Patients with Carcinoma of Unknown Primary (CUP) have widespread cancer at diagnosis however the specific site of origin cannot be found, despite significant testing, making it difficult to treat. CUP has a poor prognosis; it is the 6th most common cause of cancer death in the UK. To date there have been limited studies investigating molecular genomics in CUP patients, resulting in limited evidence to evaluate whether genomic profiling has added value over and above the standard diagnostics provided in the NHS. As a result, our project will aim to; * Assess genomic sequencing (both in tissue and blood) for the diagnosis and treatment guidance in CUP patients including a comparison of the effectiveness of tissue and blood based biomarkers * Collect evidence to further develop technology that predicts an individual's response to a treatment * Develop innovative systems of clinical data capture in patients with CUP * Investigate novel biomarkers to determine the primary tumour location Approximately 120-140 CUP patients will be recruited across 7 UK NHS sites. Tumour samples will be collected from patients undergoing a standard of care procedure OR medically fit patients with accessible tumour. Archival tumour may also be obtained. Some samples will be stored for future translational research. Sequencing results alongside clinical data will be discussed by a multi-disciplinary CUP Molecular Tumour Board. They will provide oversight on the nature, clinical significance and relevance of the results. They will inform the local CUP team of any "actionable" genetic changes, which could potentially direct selection of a targeted therapy trial for that patient. Sequential blood samples will be collected to investigate genetic characteristics that may be able to predict response to therapy. The aggregated anonymised data will be made publicly available following completion of this trial.
Detailed Description:
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Royal United Hospitals Bath NHS Foundation Trust, Bath, , United Kingdom
Velindre Cancer Centre, Cardiff, , United Kingdom
Edinburgh Cancer Centre, Edinburgh, , United Kingdom
UCL Cancer Institute, London, , United Kingdom
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Torbay Hospital, Torquay, , United Kingdom
Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, , United Kingdom